

Table S1: Summary patient demographics, pathologic features, and treatment details

Patient characteristics (n = 31)	No.	%
Age, median (range)	65	(46-82)
Gender		
Female	16	(52)
Male	15	(48)
Smoking status		
Former	22	(71)
Current	8	(26)
Never	1	(3)
Histology		
Non-squamous	28	(90)
Squamous	3	(10)
Line of therapy		
1 st	22	(71)
2 nd	5	(16)
3 rd +	4	(13)
PD-L1 expression*		
0%	6	(19)
1-49%	9	(29)
≥ 50%	16	(52)
Treatment		
Anti-PD-(L)1 monotherapy	10	(32)
Anti-PD-(L)1+CTLA-4 combination	15	(48)
Anti-PD-(L)1 combination miscellaneous	6	(19)
Anti-PD-1+bevacizumab	3	(10)
Anti-PD-L1+erlotinib [^]	2	(6)
Anti-PD-1+anti-LAG-3	1	(3)
Best overall response		
CR, complete response		
PR, partial response	7	(23)
SD, stable disease	18	(58)
	6	(19)
Tumor NGS available		
Yes	24	(77)
No	7	(23)
Tumor mutational burden/megabase, median (range)	11.6	(2.6-42.3)

*PD-L1 expression unknown for 1 patient

[^]both patients EGFR WT